Tramadol Reformulations Highlight Pain Challenges and Opportunities

While reformulating existing drugs can sometimes look like a low risk opportunity, since active substances are already deemed safe and effective, the task is often more complex. The race to develop extended release versions of the now-generic opioid tramadol showcase these technological, clinical and regulatory challenges, while demonstrating that for those who succeed, the upside can be great. A look at Pudue's deal with Labopharm and JNJ's deal with Biovail.

By Christopher Morrison

Considering the wide variety of drug delivery and formulation technologies available, the religion of life-cycle management in the pharmaceutical industry,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo